肝臓疾患治療：世界市場

当商品の販売は、2012年01月10日を持ちまして終了しました。

アップデート版はこちらになります。

原文目次

Abstract

STUDY OBJECTIVES

BCC's goal in conducting this study is to provide an overview of the current and potential aspects of the global market for liver diseases treatments. The report determines the market size and market leaders, provides a market overview, and examines factors affecting the markets for drugs used to treat liver diseases. The markets have been defined by disease type and by drug type. The overview of types of liver diseases, their symptoms and their treatments is examined along with sales figures over the five-year period from 2009 to 2014. The report also gives the demand and use criteria of the drugs used to treat liver diseases, as well as an overview of drug-induced liver diseases. Companies manufacturing and selling the drug products in this category are profiled, and factors affecting markets for these products and how the markets are likely to change are analyzed. Revenues have been broken down by the type of diseases and by different regions. Our key objective is to present a comprehensive analysis of the current market and the future direction of the drugs used to treat liver diseases.

SCOPE OF THE STUDY

The scope of this study encompasses the market for liver disease treatments. BCC analyzes each market and its leaders, the different types of liver diseases, the different types of drug products to treat liver diseases, the regulatory environment, the regional market for liver diseases and the drug products used to treat them, and market projections and market share. Technological issues include latest trends and new developments.

HIGHLIGHTS:

This Report:

• The global market for liver disease treatments amounted to nearly $8.4 billion in 2007 and is expected to increase to $9.8 billion in 2014, for a compound annual growth rate (CAGR) of 3.0%
• The treatment for hepatitis is the largest segment of the market, amounting to about $4.6 billion in the last three years, and is expected to reach $4.8 billion in 2014.
• Sales of targeted therapies were comparatively less in 2008, but this market has the potential to grow faster mainly because of the increased incidence of hepatitis C in developing countries.

METHODOLOGY

A combination of primary and secondary research methods were used in this study. A comprehensive search of literature was conducted. The literature included technical newsletters and journals as well as many other sources. The data were collected through interviews and correspondence with various pharmaceutical/ biotechnical experts. Projections were based on estimates such as the current number of end users, potential end users, likely unit prices, rates of consumption, and market trends.

INFORMATION SOURCES

BCC surveyed many companies to obtain data for this study. Included were manufacturers and the end users of the drugs used to treat liver diseases. We gathered industry data, spoke with officials from this industry, and consulted newsletters, company literature, product literature, and a host of technical articles, journals, indexes, and abstracts. Exhaustive investigations of databases by key terminology were done. In addition, we compiled data from current financial and trade information and government sources.

Table of Contents

CHAPTER 1: INTRODUCTION

• STUDY OBJECTIVES
• REASONS FOR DOING THIS STUDY
• INTENDED AUDIENCE
• SCOPE OF THE STUDY
• METHODOLOGY
• INFORMATION SOURCES
• ABOUT THE AUTHOR
• RELATED REPORTS
• BCC ONLINE SERVICES
• DISCLAIMER

CHAPTER 2: SUMMARY

• SUMMARY
• SUMMARY TABLE GLOBAL SALES OF LIVER DISEASE TREATMENTS, THROUGH 2014 ($ MILLIONS)
• SUMMARY FIGURE GLOBAL SALES OF LIVER DISEASE TREATMENTS, 2007-2014 ($ MILLIONS)

CHAPTER 3: OVERVIEW

• DEFINITIONS
• THE LIVER
  • LIVER FUNCTIONS
    • Metabolism
    • Drug Disposition
    • Bile Formation
    • Other Functions
  • COMMON SYMPTOMS OF LIVER DISEASE
    • Jaundice
    • Cholestasis
    • Liver Enlargement
    • Ascites
    • Portal Hypertension
    • Liver Encephalopathy
    • Liver Failure
    • Other Common Symptoms
  • LIVER DISEASES
• TABLE 1 TYPES OF LIVER DISEASES
  • VIRUS-INDUCED LIVER DISEASE
    • Acute Hepatitis
      • Hepatitis A
      • Hepatitis B
      • Hepatitis C
      • Hepatitis D
    • Chronic Hepatitis
      • Alcohol-induced Chronic Hepatitis
      • Chronic Active Hepatitis
      • Chronic Persistent Hepatitis
• LIVER TUMORS
  • Benign Liver Tumors
    • Hepatocellular Adenoma
    • Hemangioma
  • Malignant Liver Tumors
    • Hepatocellular Carcinoma
    • Metastatic Liver Cancer
• CONGENITAL LIVER DEFECTS
  • Biliary Atresia
  • Choledochal Cyst
• AUTOIMMUNE LIVER DISORDERS
  • Hemochromatosis
  • Wilson' s Disease
  • Autoimmune Hepatitis
• ALCOHOL-INDUCED LIVER DISEASE
  • Fatty Liver
  • Alcoholic Hepatitis
  • Alcoholic Cirrhosis
• CHRONIC LIVER DISEASE
  • Cirrhosis
  • Fibrosis
• NON-ALCOHOLIC FATTY LIVER

CHAPTER 4: REGULATORY ISSUES

• TABLE 2 APPROVED DRUGS USED TO TREAT LIVER DISEASES, 2005- 2008
• TABLE 2 (CONTINUED)
• TABLE 3 NUMBER OF NEW APPROVALS FOR DRUGS USED TO TREAT LIVER DISEASES, 2005- 2008
• FIGURE 1 NUMBER OF NEW APPROVALS FOR DRUGS USED TO TREAT LIVER DISEASES, 2005- 2008
• TABLE 4 NEW DRUG APPLICATIONS FOR DRUGS USED TO TREAT LIVER DISEASES, 2005- 2008
• TABLE 5 RECALLS OF DRUGS USED TO TREAT LIVER DISEASES, 2005- 2008
  • Hepatitis B
  • Hepatitis C
  • Hepatitis D
  • Chronic Hepatitis
  • Alcohol-induced Chronic Hepatitis
  • Chronic Active Hepatitis
  • Chronic Persistent Hepatitis
• LIVER TUMORS
  • Benign Liver Tumors
  • Hepatocellular Adenoma
  • Hemangioma
  • Malignant Liver Tumors
  • Hepatocellular Carcinoma
  • Metastatic Liver Cancer
• CONGENITAL LIVER DEFECTS
  • Biliary Atresia
  • Choledochal Cyst
• AUTOIMMUNE LIVER DISORDERS
  • Hemochromatosis
  • Wilson' s Disease
  • Autoimmune Hepatitis
• ALCOHOL-INDUCED LIVER DISEASE
  • Fatty Liver
  • Alcoholic Hepatitis
  • Alcoholic Cirrhosis
• CHRONIC LIVER DISEASE
  • Cirrhosis
  • Fibrosis
• NON-ALCOHOLIC FATTY LIVER

CHAPTER 4: REGULATORY ISSUES

• TABLE 2 APPROVED DRUGS USED TO TREAT LIVER DISEASES, 2005- 2008
• TABLE 2 (CONTINUED)
• TABLE 3 NUMBER OF NEW APPROVALS FOR DRUGS USED TO TREAT LIVER DISEASES, 2005- 2008
• FIGURE 1 NUMBER OF NEW APPROVALS FOR DRUGS USED TO TREAT LIVER DISEASES, 2005- 2008
• TABLE 4 NEW DRUG APPLICATIONS FOR DRUGS USED TO TREAT LIVER DISEASES, 2005- 2008
• TABLE 5 RECALLS OF DRUGS USED TO TREAT LIVER DISEASES, 2005- 2008
• TABLE 19 IMMUNOSUPPRESSIVE AGENTS USED TO TREAT AUTOIMMUNE HEPATITIS
• ANTIMETABOLITES
• TABLE 20 ANTI-METABOLITES USED TO TREAT AUTOIMMUNE HEPATITIS
• ALCOHOL-INDUCED LIVER DISEASE
• ANABOLIC STEROIDS
• TABLE 21 ANABOLIC STEROIDS USED TO TREAT ALCOHOLIC LIVER DAMAGE
• ALCOHOL ABUSE DRUGS
• TABLE 22 ALCOHOL ABUSE DRUGS USED TO TREAT ALCOHOLIC LIVER DAMAGE
• CHRONIC LIVER DISEASE
• ANTI-REJECTION MEDICATION
• TABLE 23 ANTI-REJECTION MEDICATIONS
• ANTI-INFECTIVES
• TABLE 24 ANTI-INFECTIVES
• ANTIFUNGAL PROPHYLAXIS
• TABLE 25 ANTIFUNGAL PROPHYLAXIS FOR LIVER TRANSPLANT RECIPIENTS
• NON-ALCOHOLIC FATTY LIVER
• GALLSTONE SOLUBILIZING AGENTS
• TABLE 26 GALLSTONE SOLUBILIZING AGENTS USED TO TREAT NON- ALCOHOLIC FATTY LIVER DISEASE
• OTHER DRUGS
• TABLE 27 OTHER DRUGS USED TO TREAT NON-ALCOHOLIC FATTY LIVER DISEASE

CHAPTER 7: INDUSTRY STRUCTURE

• HEPATITIS
• HEPATITIS VACCINE
• TABLE 28 HEPATITIS VACCINE: MARKET SHARE BY MANUFACTURER, 2008 (%)
• FIGURE 2 HEPATITIS VACCINE: MARKET SHARE BY MANUFACTURER, 2008
• NUCLEOSIDE ANALOGS
• TABLE 29 NUCLEOSIDE ANALOGS TO TREAT HEPATITIS: MARKET SHARE BY MANUFACTURER, 2008 (%)
• FIGURE 3 NUCLEOSIDE ANALOGS TO TREAT HEPATITIS: MARKET SHARE BY MANUFACTURER, 2008 (%)
• NUCLEOTIDE ANALOGS
• TABLE 19 IMMUNOSUPPRESSIVE AGENTS USED TO TREAT AUTOIMMUNE HEPATITIS
• ANTIMETABOLITES
• TABLE 20 ANTI-METABOLITES USED TO TREAT AUTOIMMUNE HEPATITIS
• ALCOHOL-INDUCED LIVER DISEASE
• ANABOLIC STEROIDS
• TABLE 21 ANABOLIC STEROIDS USED TO TREAT ALCOHOLIC LIVER DAMAGE
• ALCOHOL ABUSE DRUGS
• TABLE 22 ALCOHOL ABUSE DRUGS USED TO TREAT ALCOHOLIC LIVER DAMAGE
• CHRONIC LIVER DISEASE
• ANTI-REJECTION MEDICATION
• TABLE 23 ANTI-REJECTION MEDICATIONS
• ANTI-INFECTIVES
• TABLE 24 ANTI-INFECTIVES
• ANTIFUNGAL PROPHYLAXIS
• TABLE 25 ANTIFUNGAL PROPHYLAXIS FOR LIVER TRANSPLANT RECIPIENTS
• NON-ALCOHOLIC FATTY LIVER
• GALLSTONE SOLUBILIZING AGENTS
• TABLE 26 GALLSTONE SOLUBILIZING AGENTS USED TO TREAT NON- ALCOHOLIC FATTY LIVER DISEASE
• OTHER DRUGS
• TABLE 27 OTHER DRUGS USED TO TREAT NON-ALCOHOLIC FATTY LIVER DISEASE

CHAPTER 7: INDUSTRY STRUCTURE

• HEPATITIS
• HEPATITIS VACCINE
• TABLE 28 HEPATITIS VACCINE: MARKET SHARE BY MANUFACTURER, 2008 (%)
• FIGURE 2 HEPATITIS VACCINE: MARKET SHARE BY MANUFACTURER, 2008
• NUCLEOSIDE ANALOGS
• TABLE 29 NUCLEOSIDE ANALOGS TO TREAT HEPATITIS: MARKET SHARE BY MANUFACTURER, 2008 (%)
• FIGURE 3 NUCLEOSIDE ANALOGS TO TREAT HEPATITIS: MARKET SHARE BY MANUFACTURER, 2008 (%)
• NUCLEOTIDE ANALOGS
• TABLE 30 NUCLEOTIDE ANALOGS TO TREAT HEPATITIS: MARKET SHARE BY MANUFACTURER: 2008 (%)
• FIGURE 4 NUCLEOTIDE ANALOGS TO TREAT HEPATITS: MARKET SHARE BY MANUFACTURER, 2008 (%)
• INTERFERONS
• TABLE 31 INTERFERONS TO TREAT HEPATITIS: MARKET SHARE BY MANUFACTURER, 2008 (%)
• FIGURE 5 INTERFERONS TO TREAT HEPATITIS: MARKET SHARE BY MANUFACTURER, 2008 (%)
• IMMUNE GLOBULINS
• TABLE 32 IMMUNE GLOBULINS TO TREAT HEPATITIS: MARKET SHARE BY MANUFACTURER, 2008 (%)
• FIGURE 6 IMMUNE GLOBULINS TO TREAT HEPATITIS: MARKET SHARE BY MANUFACTURER, 2008 (%)
• LIVER TUMORS
• CHEMOTHERAPY
• TABLE 33 CHEMOTHERAPY TO TREAT LIVER TUMORS: MARKET SHARE BY MANUFACTURER, 2008 (%)
• FIGURE 7 CHEMOTHERAPY TO TREAT LIVER TUMORS: MARKET SHARE BY MANUFACTURER, 2008 (%)
• TARGETED THERAPY
• TABLE 34 TARGETED THERAPY TO TREAT LIVER TUMORS: MARKET SHARE BY MANUFACTURER, 2008 (%)
• FIGURE 8 TARGETED THERAPY TO TREAT LIVER TUMORS: MARKET SHARE BY MANUFACTURER, 2008 (%)
• AUTOIMMUNE DISEASES
• CHELATING AGENTS
• TABLE 35 CHELATING AGENTS TO TREAT AUTOIMMUNE LIVER DISEASE: MARKET SHARE BY MANUFACTURER, 2008 (%)
• FIGURE 9 CHELATING AGENTS TO TREAT AUTOIMMUNE LIVER DISEASE: MARKET SHARE BY MANUFACTURER, 2008 (%)
• CORTICOSTEROIDS
• TABLE 36 CORTICOSTEROIDS TO TREAT AUTOIMMUNE LIVER DISEASE: MARKET SHARE BY MANUFACTURER, 2008 (%)
• FIGURE 10 CORTICOSTEROIDS TO TREAT AUTOIMMUNE LIVER DISEASE: MARKET SHARE BY MANUFACTURER, 2008 (%)
• IMMUNOSUPPRESSIVE AGENTS
• TABLE 37 IMMUNOSUPPRESSIVE AGENTS TO TREAT AUTOIMMUNE LIVER DISEASE: MARKET SHARE BY MANUFACTURER, 2008 (%)
• TABLE 45 OTHER DRUGS USED TO TREAT NON-ALCOHOLIC FATTY LIVER DISEASE: MARKET SHARE BY MANUFACTURER, 2008 (%)
• FIGURE 19 OTHER DRUGS USED TO TREAT NON-ALCOHOLIC FATTY LIVER DISEASE: MARKET SHARE BY MANUFACTURER, 2008 (%)

CHAPTER 8: DEMAND AND USE

• LIFE EXPECTANCY
• LACK OF KNOWLEDGE
• LACK OF TREATMENT OPTIONS
• INCREASING NUMBER OF PATIENTS
• RESEARCH AND DEVELOPMENT
• INITIATIVES OF VARIOUS ORGANIZATIONS TO INCREASE AWARENESS
• INITIATIVES OF VARIOUS ORGANIZATIONS ... (CONTINUED)

CHAPTER 9: MARKET ANALYSIS

• TABLE 46 GLOBAL SALES OF DRUGS USED TO TREAT LIVER DISEASES, BY DISEASE TYPE, THROUGH 2014 ($ MILLIONS)
• FIGURE 20 GLOBAL SALES OF DRUGS USED TO TREAT LIVER DISEASES, BY DISEASE TYPE, 2007-2014 ($ MILLIONS)
• HEPATITIS
• MARKET SIZE
• TABLE 47 GLOBAL SALES OF DRUGS TO TREAT HEPATITIS, THROUGH 2014 ($ MILLIONS)
• FIGURE 21 GLOBAL SALES OF DRUGS TO TREAT HEPATITIS, 2007-2014 ($ MILLIONS)
• MARKET OVERVIEW
• Market Overview (Continued)
• LIVER TUMORS
• MARKET SIZE
• TABLE 48 GLOBAL SALES OF DRUGS TO TREAT LIVER TUMORS, THROUGH 2014 ($ MILLIONS)
• FIGURE 22 GLOBAL SALES OF DRUGS TO TREAT LIVER TUMORS, 2007-2014 ($ MILLIONS)
• MARKET OVERVIEW
• AUTOIMMUNE DISEASES
• MARKET SIZE
• TABLE 49 GLOBAL SALES OF DRUGS TO TREAT AUTOIMMUNE DISEASES, THROUGH 2014 ($ MILLIONS)
• TABLE 45 OTHER DRUGS USED TO TREAT NON-ALCOHOLIC FATTY LIVER DISEASE: MARKET SHARE BY MANUFACTURER, 2008 (%)
• FIGURE 19 OTHER DRUGS USED TO TREAT NON-ALCOHOLIC FATTY LIVER DISEASE: MARKET SHARE BY MANUFACTURER, 2008 (%)

CHAPTER 8: DEMAND AND USE

• LIFE EXPECTANCY
• LACK OF KNOWLEDGE
• LACK OF TREATMENT OPTIONS
• INCREASING NUMBER OF PATIENTS
• RESEARCH AND DEVELOPMENT
• INITIATIVES OF VARIOUS ORGANIZATIONS TO INCREASE AWARENESS
• INITIATIVES OF VARIOUS ORGANIZATIONS ... (CONTINUED)

CHAPTER 9: MARKET ANALYSIS

• TABLE 46 GLOBAL SALES OF DRUGS USED TO TREAT LIVER DISEASES, BY DISEASE TYPE, THROUGH 2014 ($ MILLIONS)
• FIGURE 20 GLOBAL SALES OF DRUGS USED TO TREAT LIVER DISEASES, BY DISEASE TYPE, 2007-2014 ($ MILLIONS)
• HEPATITIS
• MARKET SIZE
• TABLE 47 GLOBAL SALES OF DRUGS TO TREAT HEPATITIS, THROUGH 2014 ($ MILLIONS)
• FIGURE 21 GLOBAL SALES OF DRUGS TO TREAT HEPATITIS, 2007-2014 ($ MILLIONS)
• MARKET OVERVIEW
  • Market Overview (Continued)
• LIVER TUMORS
• MARKET SIZE
• TABLE 48 GLOBAL SALES OF DRUGS TO TREAT LIVER TUMORS, THROUGH 2014 ($ MILLIONS)
• FIGURE 22 GLOBAL SALES OF DRUGS TO TREAT LIVER TUMORS, 2007-2014 ($ MILLIONS)
• MARKET OVERVIEW
• AUTOIMMUNE DISEASES
• MARKET SIZE
• TABLE 49 GLOBAL SALES OF DRUGS TO TREAT AUTOIMMUNE DISEASES, THROUGH 2014 ($ MILLIONS)
• FIGURE 23 GLOBAL SALES OF DRUGS TO TREAT AUTOIMMUNE DISEASES, THROUGH 2014 ($ MILLIONS)
• MARKET OVERVIEW
• ALCOHOL-INDUCED LIVER DISEASE
• MARKET SIZE
• TABLE 50 GLOBAL SALES OF DRUGS TO TREAT ALCOHOL-INDUCED LIVER DISEASES, THROUGH 2014 ($ MILLIONS)
• FIGURE 24 GLOBAL SALES OF DRUGS TO TREAT ALCOHOL-INDUCED LIVER DISEASES, 2007-2014 ($ MILLIONS)
• MARKET OVERVIEW
• CHRONIC LIVER DISEASES
• MARKET SIZE
• TABLE 51 GLOBAL SALES OF DRUGS TO TREAT CHRONIC LIVER DISEASES, THROUGH 2014 ($ MILLIONS)
• FIGURE 25 GLOBAL SALES OF DRUGS TO TREAT CHRONIC LIVER DISEASES, 2007-2014 ($ MILLIONS)
• MARKET OVERVIEW
• NON-ALCOHOLIC FATTY LIVER DISEASE
• MARKET SIZE
• TABLE 52 GLOBAL SALES OF DRUGS TO TREAT NON-ALCOHOLIC FATTY LIVER DISEASES, THROUGH 2014 ($ MILLIONS)
• FIGURE 26 GLOBAL SALES OF DRUGS TO TREAT NON-ALCOHOLIC FATTY LIVER DISEASES, 2007-2094 ($ MILLIONS)
• MARKET OVERVIEW
  • Market Overview (Continued)

CHAPTER 10: DRUG-INDUCED LIVER DISEASE

• DRUG-INDUCED
• DRUGS THAT CAN CAUSE LIVER DISEASE
• ACETAMINOPHEN (TYLENOL)
• STATINS
• NICOTINIC ACID (NIACIN)
• AMIODARONE (CORDARONE)
• NONSTEROIDAL ANTI-INFLAMMATORY DRUGS
• METHOTREXATE (RHEUMATREX, TREXALL)
• ANTIBIOTICS
• TACRINE (COGNEX)
• DISULFIRAM
• VITAMIN SUPPLEMENTS
• TABLE 53 DRUGS THAT CAN CAUSE LIVER DISEASE
• TABLE 53 (CONTINUED)

CHAPTER 11: NEW DEVELOPMENTS

• CLINICAL TRIALS
• TABLE 54 NUMBER OF CLINICAL TRIALS FOR HEPATITIS/ LIVER-INDUCED LIVER DISEASES
• TABLE 55 NUMBER OF CLINICAL TRIALS FOR LIVER TUMORS
• TABLE 56 NUMBER OF CLINICAL TRIALS FOR CONGENITAL LIVER DEFECTS
• TABLE 57 NUMBER OF CLINICAL TRIALS FOR AUTOIMMUNE LIVER DISORDERS
• TABLE 58 NUMBER OF CLINICAL TRIALS FOR ALCOHOL-INDUCED LIVER DISEASES
• TABLE 59 NUMBER OF CLINICAL TRIALS FOR CHRONIC LIVER DISEASES
• TABLE 60 NUMBER OF CLINICAL TRIALS FOR NON-ALCOHOLIC FATTY LIVER DISEASE
• NEW DEVELOPMENTS
• NEW DEVELOPMENTS (CONTINUED)
• STEM CELL RESEARCH

CHAPTER 12: MARKET BY DRUG TYPE

• MARKET SIZE
• TABLE 61 GLOBAL SALES OF DRUGS USED TO TREAT LIVER DISEASES, THROUGH 2014 ($ MILLIONS)
• TABLE 61 (CONTINUED)
• FIGURE 27 GLOBAL SALES OF DRUGS USED TO TREAT LIVER DISEASES, 2007-2014 ($ MILLIONS)
• MARKET SHARE
• TABLE 62 SHARE OF DRUGS TO TREAT LIVER DISEASES, 2008
• FIGURE 28 SHARE OF DRUGS TO TREAT LIVER DISEASES, 2008 (%)
• VACCINES
• MARKET SIZE
• TABLE 63 GLOBAL SALES OF HEPATITIS VACCINE,THROUGH 2014 ($ MILLIONS)
• FIGURE 29 GLOBAL SALES OF HEPATITIS VACCINE, 2007-2014 ($ MILLIONS)
• ANTIVIRALS
• MARKET SIZE
• TABLE 64 GLOBAL SALES OF NUCLEOSIDE ANALOGS TO TREAT LIVER DISEASES, BY REGION, THROUGH 2014 ($ MILLIONS)
• FIGURE 30 GLOBAL SALES OF NUCLEOSIDE ANALOGS TO TREAT LIVER DISEASES, BY REGION, 2007-2014 ($ MILLIONS)
• TABLE 65 GLOBAL SALES OF NUCLEOTIDE ANALOGS TO TREAT LIVER DISEASES, BY REGION, THROUGH 2014 ($ MILLIONS)
• FIGURE 31 GLOBAL SALES OF NUCLEOTIDE ANALOGS TO TREAT LIVER DISEASES, BY REGION, 2007-2014 ($ MILLIONS)
• INTERFERONS
• MARKET SIZE
• TABLE 66 GLOBAL SALES OF INTERFERONS TO TREAT LIVER DISEASES, BY REGION, THROUGH 2014 ($ MILLIONS)
• FIGURE 32 GLOBAL SALES OF INTERFERONS TO TREAT LIVER DISEASES, BY REGION, 2007-2014 ($ MILLIONS)
• IMMUNE GLOBULINS
• MARKET SIZE
• TABLE 67 GLOBAL SALES OF IMMUNE GLOBULINS TO TREAT LIVER DISEASES, BY REGION, THROUGH 2014 ($ MILLIONS)
• FIGURE 33 GLOBAL SALES OF IMMUNE GLOBULINS TO TREAT LIVER DISEASES, BY REGION, 2007-2014 ($ MILLIONS)
• CHEMOTHERAPY
• MARKET SIZE
• TABLE 68 GLOBAL SALES OF CHEMOTHERAPY DRUGS TO TREAT LIVER DISEASES, BY REGION, THROUGH 2014 ($ MILLIONS)
• FIGURE 34 GLOBAL SALES OF CHEMOTHERAPY DRUGS TO TREAT LIVER DISEASES, BY REGION, 2007-2014 ($ MILLIONS)
• TARGETED THERAPY
• MARKET SIZE
• TABLE 69 GLOBAL SALES OF TARGETED THERAPY TO TREAT LIVER CANCER, BY REGION, THROUGH 2014 ($ MILLIONS)
• FIGURE 35 GLOBAL SALES OF TARGETED THERAPY TO TREAT LIVER CANCER, BY REGION, 2007-2014 ($ MILLIONS)
• CHELATING AGENTS
• MARKET SIZE
• TABLE 70 GLOBAL SALES OF CHELATING AGENTS TO TREAT LIVER DISEASES, BY REGION, THROUGH 2014 ($ MILLIONS)
• FIGURE 36 GLOBAL SALES OF CHELATING AGENTS TO TREAT LIVER DISEASES, BY REGION, 2007-2014 ($ MILLIONS)
• CORTICOSTEROIDS
• MARKET SIZE
• TABLE 71 GLOBAL SALES OF CORTICOSTEROIDS TO TREAT LIVER DISEASES, BY REGION, THROUGH 2014 ($ MILLIONS)
• FIGURE 37 GLOBAL SALES OF CORTICOSTEROIDS TO TREAT LIVER DISEASES, BY REGION, 2007-2014 ($ MILLIONS)
• IMMUNOSUPPRESSIVE AGENTS
• MARKET SIZE
• TABLE 72 GLOBAL SALES OF IMMUNOSUPPRESSIVE AGENTS TO TREAT LIVER DISEASES, BY REGION, THROUGH 2014 ($ MILLIONS)
• FIGURE 38 GLOBAL SALES OF IMMUNOSUPPRESSIVE AGENTS TO TREAT LIVER DISEASES, BY REGION, 2007-2014 ($ MILLIONS)
• ANTIMETABOLITES
• MARKET SIZE
• TABLE 73 GLOBAL SALES OF ANTIMETABOLITES TO TREAT LIVER DISEASES, BY REGION, THROUGH 2014 ($ MILLIONS)
• FIGURE 39 GLOBAL SALES OF ANTIMETABOLITES TO TREAT LIVER DISEASES, BY REGION, 2007-2014 ($ MILLIONS)
• ANABOLIC STEROIDS
• MARKET SIZE
• TABLE 74 GLOBAL SALES OF ANABOLIC STEROIDS TO TREAT LIVER DISEASES, BY REGION, THROUGH 2014 ($ MILLIONS)
• FIGURE 40 GLOBAL SALES OF ANABOLIC STEROIDS TO TREAT LIVER DISEASES, BY REGION, 2007-2014 ($ MILLIONS)
• ALCOHOL ABUSE DRUGS
• MARKET SIZE
• TABLE 75 GLOBAL SALES OF ALCOHOL ABUSE DRUGS, BY REGION, THROUGH 2014 ($ MILLIONS)
• FIGURE 41 GLOBAL SALES OF ALCOHOL ABUSE DRUGS, BY REGION, 2007-2014 ($ MILLIONS)
• ANTI-REJECTION MEDICATION
• MARKET SIZE
• TABLE 76 GLOBAL SALES OF ANTI-REJECTION MEDICATION TO TREAT LIVER DISEASES, BY REGION, THROUGH 2014 ($ MILLIONS)
• FIGURE 42 GLOBAL SALES OF ANTI-REJECTION MEDICATION TO TREAT LIVER DISEASES, BY REGION, 2007-2014 ($ MILLIONS)
• INFECTION-FIGHTING DRUGS
• MARKET SIZE
• TABLE 77 GLOBAL SALES OF INFECTION-FIGHTING DRUGS TO TREAT LIVER TRANSPLANT PATIENTS, BY REGION, THROUGH 2014 ($ MILLIONS)
• FIGURE 43 GLOBAL SALES OF INFECTION-FIGHTING DRUGS TO TREAT LIVER TRANSPLANT PATIENTS, BY REGION, 2007-2014 ($ MILLIONS)
• ANTIFUNGAL PROPHYLAXIS
• MARKET SIZE
• TABLE 78 GLOBAL SALES OF ANTIFUNGAL PROPHYLAXIS IN LIVER TRANSPLANTS, BY REGION, THROUGH 2014 ($ MILLIONS)
• FIGURE 44 GLOBAL SALES OF ANTIFUNGAL PROPHYLAXIS IN LIVER TRANSPLANTS, BY REGION, 2007-2014 ($ MILLIONS)
• GALLSTONE SOLUBILIZING AGENTS
• MARKET SIZE
• TABLE 79 GLOBAL SALES OF GALLSTONE SOLUBILIZING AGENTS, BY REGION, THROUGH 2014 ($ MILLIONS)
• FIGURE 45 GLOBAL SALES OF GALLSTONE SOLUBILIZING AGENTS, BY REGION, 2007-2014 ($ MILLIONS)
• OTHER DRUGS USED TO TREAT NON-ALCOHOLIC FATTY LIVER DISEASES
• MARKET SIZE
• TABLE 80 GLOBAL SALES OF OTHER DRUGS USED TO TREAT NON- ALCOHOLIC FATTY LIVER DISEASES, BY REGION, THROUGH 2014 ($ MILLIONS)
• FIGURE 46 GLOBAL SALES OF OTHER DRUGS USED IN THE TREATMENT OF NON- ALCOHOLIC FATTY LIVER DISEASES, BY REGION, 2007-2014 ($ MILLIONS)
• CHAPTER 13: PATENT ANALYSIS
• PATENTS BY YEAR
• TABLE 81 TOTAL NUMBER OF PATENTS EACH YEAR, 2005- 2009
• FIGURE 47 TOTAL NUMBER OF PATENTS EACH YEAR, 2005- 2009
• PATENTS BY TYPE
• TABLE 82 NUMBER OF PATENTS BY TYPE, 2005- 2009
• FIGURE 48 NUMBER OF PATENTS BY TYPE, 2005- 2009
• FIGURE 49 PATENTS, SHARE BY TYPE, 2005- 2009 (%)
• PATENTS BY COUNTRY
• TABLE 83 TOTAL NUMBER OF PATENTS BY COUNTRY, 2005- 2009
• FIGURE 50 TOTAL NUMBER OF PATENTS BY COUNTRY, 2005- 2009
• PATENTS BY COMPANY
• TABLE 84 NUMBER OF PATENTS BY COMPANY, 2005- 2009
• FIGURE 51 TOTAL NUMBER OF PATENTS BY COMPANY, 2005- 2009
• PATENTS BY ASSIGNEE
• TABLE 85 NUMBER OF PATENTS BY ASIGNEE, 2005- 2009
• FIGURE 52 NUMBER OF PATENTS BY ASSIGNEE, 2005- 2009

CHAPTER 14: COMPANY PROFILES

• ABBOTT LABORATORIES
• ACTAVIS US
• ALKERMES, INC.
• ALNYLAM PHARMACEUTICALS
• BARR PHARMACEUTICALS
• BAYER SCHERING PHARMA AG
• BIOTEST PHARMACEUTICALS CORPORATION
• BRISTOL-MYERS SQUIBB
• CANGENE CORPORATION
• DEBIOPHARM GROUP
• ELI LILLY & COMPANY
• GALMED MEDICAL RESEARCH, LTD.
• GILEAD SCIENCES, INC.
• GLAXOSMITHKLINE PLC
• HUMAN GENOME SCIENCES
• IDENIX PHARMACEUTICALS INC.
• KINEMED, INC.
• MALLINCKRODT
• MEDA PHARMACEUTICALS
• MERCK & CO.
• NOVARTIS AG
• PAR PHARMACEUTICAL COMPANIES, INC.
• ROCHE
• ROXANE LABORATORIES, INC.
• SANOFI AVENTIS
• SAVIENT PHARMACEUTICALS, INC.
• SCHERING-PLOUGH
• SCYNEXIS
• TEVA PHARMACEUTICAL INDUSTRIES LTD.
• THREE RIVERS PHARMACEUTICALS
• VALEANT PHARMACEUTICALS INTERNATIONAL
• WATSON PHARMACEUTICALS, INC.
• WYETH INC.
• ZYDUS PHARMACEUTICALS INC.
• ZYMOGENETICS
• APPENDIX
• ABBREVIATIONS

LIST OF TABLES

• SUMMARY TABLE GLOBAL SALES OF LIVER DISEASE TREATMENTS, THROUGH 2014 ($ MILLIONS)
• TABLE 1 TYPES OF LIVER DISEASES
• TABLE 2 APPROVED DRUGS USED TO TREAT LIVER DISEASES, 2005- 2008
• TABLE 3 NUMBER OF NEW APPROVALS FOR DRUGS USED TO TREAT LIVER DISEASES, 2005- 2008
• TABLE 4 NEW DRUG APPLICATIONS FOR DRUGS USED TO TREAT LIVER DISEASES, 2005- 2008
• TABLE 5 RECALLS OF DRUGS USED TO TREAT LIVER DISEASES, 2005- 2008
• TABLE 6 HEPATITIS BURDEN IN THE UNITED STATES (2005- 2006)
• TABLE 7 INCIDENCE OF ACUTE HEPATITIS BY SEX AND AGE IN THE UNITED STATES (2006)
• TABLE 8 VACCINES FOR HEPATITIS A PREVENTION
• TABLE 9 VACCINES FOR HEPATITIS B PREVENTION
• TABLE 10 NUCLEOSIDE ANALOGS USED TO TREAT HEPATITIS
• TABLE 11 NUCLEOTIDE ANALOGS USED TO TREAT HEPATITIS
• TABLE 12 PROTEASE INHIBITORS USED TO TREAT HEPATITIS
• TABLE 13 INTERFERONS USED TO TREAT HEPATITIS
• TABLE 14 IMMUNE GLOBULINS USED TO TREAT HEPATITIS
• TABLE 15 CHEMOTHERAPUTIC DRUGS USED TO TREAT LIVER CANCER
• TABLE 16 TARGETED THERAPY USED TO TREAT LIVER CANCER
• TABLE 17 DRUGS USED TO TREAT WILSON' S DISEASE
• TABLE 18 CORTICOSTEROIDS USED TO TREAT AUTOIMMUNE HEPATITIS
• TABLE 19 IMMUNOSUPPRESSIVE AGENTS USED TO TREAT AUTOIMMUNE HEPATITIS
• TABLE 20 ANTI-METABOLITES USED TO TREAT AUTOIMMUNE HEPATITIS
• TABLE 21 ANABOLIC STEROIDS USED TO TREAT ALCOHOLIC LIVER DAMAGE
• TABLE 22 ALCOHOL ABUSE DRUGS USED TO TREAT ALCOHOLIC LIVER DAMAGE
• TABLE 23 ANTI-REJECTION MEDICATIONS
• TABLE 24 ANTI-INFECTIVES
• TABLE 25 ANTIFUNGAL PROPHYLAXIS FOR LIVER TRANSPLANT RECIPIENTS
• TABLE 26 GALLSTONE SOLUBILIZING AGENTS USED TO TREAT NON- ALCOHOLIC FATTY LIVER DISEASE
• TABLE 27 OTHER DRUGS USED TO TREAT NON-ALCOHOLIC FATTY LIVER DISEASE
• TABLE 28 HEPATITIS VACCINE: MARKET SHARE BY MANUFACTURER, 2008 (%)
• TABLE 29 NUCLEOSIDE ANALOGS TO TREAT HEPATITIS: MARKET SHARE BY MANUFACTURER, 2008 (%)
• TABLE 30 NUCLEOTIDE ANALOGS TO TREAT HEPATITIS: MARKET SHARE BY MANUFACTURER: 2008 (%)
• TABLE 31 INTERFERONS TO TREAT HEPATITIS: MARKET SHARE BY MANUFACTURER, 2008 (%)
• TABLE 32 IMMUNE GLOBULINS TO TREAT HEPATITIS: MARKET SHARE BY MANUFACTURER, 2008 (%)
• TABLE 33 CHEMOTHERAPY TO TREAT LIVER TUMORS: MARKET SHARE BY MANUFACTURER, 2008 (%)
• TABLE 34 TARGETED THERAPY TO TREAT LIVER TUMORS: MARKET SHARE BY MANUFACTURER, 2008 (%)
• TABLE 35 CHELATING AGENTS TO TREAT AUTOIMMUNE LIVER DISEASE: MARKET SHARE BY MANUFACTURER, 2008 (%)
• TABLE 36 CORTICOSTEROIDS TO TREAT AUTOIMMUNE LIVER DISEASE: MARKET SHARE BY MANUFACTURER, 2008 (%)
• TABLE 37 IMMUNOSUPPRESSIVE AGENTS TO TREAT AUTOIMMUNE LIVER DISEASE: MARKET SHARE BY MANUFACTURER, 2008 (%)
• TABLE 38 ANTIMETABOLITES TO TREAT AUTOIMMUNE LIVER DISEASE: MARKET SHARE BY MANUFACTURER, 2008 (%)
• TABLE 39 ANABOLIC STEROIDS TO TREAT ALCOHOL-INDUCED LIVER DISEASE: MARKET SHARE BY MANUFACTURER, 2008 (%)
• TABLE 40 ALCOHOL ABUSE DRUGS: MARKET SHARE BY MANUFACTURER, 2008 (%)
• TABLE 41 ANTI-REJECTION MEDICATION TO TREAT CHRONIC LIVER DISEASE: MARKET SHARE BY MANUFACTURER, 2008 (%)
• TABLE 42 ANTI-INFECTIVES TO TREAT CHRONIC LIVER DISEASE: MARKET SHARE BY MANUFACTURER, 2008 (%)
• TABLE 43 ANTIFUNGAL PROPHYLAXIS TO TREAT CHRONIC LIVER DISEASE: MARKET SHARE BY MANUFACTURER, 2008 (%)
• TABLE 44 GALLSTONE STABILIZING AGENTS: MARKET SHARE BY MANUFACTURER, 2008 (%)
• TABLE 45 OTHER DRUGS USED TO TREAT NON-ALCOHOLIC FATTY LIVER DISEASE: MARKET SHARE BY MANUFACTURER, 2008 (%)
• TABLE 46 GLOBAL SALES OF DRUGS USED TO TREAT LIVER DISEASES, BY DISEASE TYPE, THROUGH 2014 ($ MILLIONS)
• TABLE 47 GLOBAL SALES OF DRUGS TO TREAT HEPATITIS, THROUGH 2014 ($ MILLIONS)
• TABLE 48 GLOBAL SALES OF DRUGS TO TREAT LIVER TUMORS, THROUGH 2014 ($ MILLIONS)
• TABLE 49 GLOBAL SALES OF DRUGS TO TREAT AUTOIMMUNE DISEASES, THROUGH 2014 ($ MILLIONS)
• TABLE 50 GLOBAL SALES OF DRUGS TO TREAT ALCOHOL-INDUCED LIVER DISEASES, THROUGH 2014 ($ MILLIONS)
• TABLE 51 GLOBAL SALES OF DRUGS TO TREAT CHRONIC LIVER DISEASES, THROUGH 2014 ($ MILLIONS)
• TABLE 52 GLOBAL SALES OF DRUGS TO TREAT NON-ALCOHOLIC FATTY LIVER DISEASES, THROUGH 2014 ($ MILLIONS)
• TABLE 53 DRUGS THAT CAN CAUSE LIVER DISEASE
• TABLE 54 NUMBER OF CLINICAL TRIALS FOR HEPATITIS/ LIVER-INDUCED LIVER DISEASES
• TABLE 55 NUMBER OF CLINICAL TRIALS FOR LIVER TUMORS
• TABLE 56 NUMBER OF CLINICAL TRIALS FOR CONGENITAL LIVER DEFECTS
• TABLE 57 NUMBER OF CLINICAL TRIALS FOR AUTOIMMUNE LIVER DISORDERS
• TABLE 58 NUMBER OF CLINICAL TRIALS FOR ALCOHOL-INDUCED LIVER DISEASES
• TABLE 59 NUMBER OF CLINICAL TRIALS FOR CHRONIC LIVER DISEASES
• TABLE 60 NUMBER OF CLINICAL TRIALS FOR NON-ALCOHOLIC FATTY LIVER DISEASE
• TABLE 61 GLOBAL SALES OF DRUGS USED TO TREAT LIVER DISEASES, THROUGH 2014 ($ MILLIONS)
• TABLE 62 SHARE OF DRUGS TO TREAT LIVER DISEASES, 2008
• TABLE 63 GLOBAL SALES OF HEPATITIS VACCINE,THROUGH 2014 ($ MILLIONS)
• TABLE 64 GLOBAL SALES OF NUCLEOSIDE ANALOGS TO TREAT LIVER DISEASES, BY REGION, THROUGH 2014 ($ MILLIONS)
• TABLE 65 GLOBAL SALES OF NUCLEOTIDE ANALOGS TO TREAT LIVER DISEASES, BY REGION, THROUGH 2014 ($ MILLIONS)
• TABLE 66 GLOBAL SALES OF INTERFERONS TO TREAT LIVER DISEASES, BY REGION, THROUGH 2014 ($ MILLIONS)
• TABLE 67 GLOBAL SALES OF IMMUNE GLOBULINS TO TREAT LIVER DISEASES, BY REGION, THROUGH 2014 ($ MILLIONS)
• TABLE 68 GLOBAL SALES OF CHEMOTHERAPY DRUGS TO TREAT LIVER DISEASES, BY REGION, THROUGH 2014 ($ MILLIONS)
• TABLE 69 GLOBAL SALES OF TARGETED THERAPY TO TREAT LIVER CANCER, BY REGION, THROUGH 2014 ($ MILLIONS)
• TABLE 70 GLOBAL SALES OF CHELATING AGENTS TO TREAT LIVER DISEASES, BY REGION, THROUGH 2014 ($ MILLIONS)
• TABLE 71 GLOBAL SALES OF CORTICOSTEROIDS TO TREAT LIVER DISEASES, BY REGION, THROUGH 2014 ($ MILLIONS)
• TABLE 72 GLOBAL SALES OF IMMUNOSUPPRESSIVE AGENTS TO TREAT LIVER DISEASES, BY REGION, THROUGH 2014 ($ MILLIONS)
• TABLE 73 GLOBAL SALES OF ANTIMETABOLITES TO TREAT LIVER DISEASES, BY REGION, THROUGH 2014 ($ MILLIONS)
• TABLE 74 GLOBAL SALES OF ANABOLIC STEROIDS TO TREAT LIVER DISEASES, BY REGION, THROUGH 2014 ($ MILLIONS)
• TABLE 75 GLOBAL SALES OF ALCOHOL ABUSE DRUGS, BY REGION, THROUGH 2014 ($ MILLIONS)
• TABLE 76 GLOBAL SALES OF ANTI-REJECTION MEDICATION TO TREAT LIVER DISEASES, BY REGION, THROUGH 2014 ($ MILLIONS)
• TABLE 77 GLOBAL SALES OF INFECTION-FIGHTING DRUGS TO TREAT LIVER TRANSPLANT PATIENTS, BY REGION, THROUGH 2014 ($ MILLIONS)
• TABLE 78 GLOBAL SALES OF ANTIFUNGAL PROPHYLAXIS IN LIVER TRANSPLANTS, BY REGION, THROUGH 2014 ($ MILLIONS)
• TABLE 79 GLOBAL SALES OF GALLSTONE SOLUBILIZING AGENTS, BY REGION, THROUGH 2014 ($ MILLIONS)
• TABLE 80 GLOBAL SALES OF OTHER DRUGS USED TO TREAT NON- ALCOHOLIC FATTY LIVER DISEASES, BY REGION, THROUGH 2014 ($ MILLIONS)
• TABLE 81 TOTAL NUMBER OF PATENTS EACH YEAR, 2005- 2009
• TABLE 82 NUMBER OF PATENTS BY TYPE, 2005- 2009
• TABLE 83 TOTAL NUMBER OF PATENTS BY COUNTRY, 2005- 2009
• TABLE 84 NUMBER OF PATENTS BY COMPANY, 2005- 2009
• TABLE 85 NUMBER OF PATENTS BY ASIGNEE, 2005- 2009

LIST OF FIGURES

• SUMMARY FIGURE GLOBAL SALES OF LIVER DISEASE TREATMENTS, 2007-2014 ($ MILLIONS)
• FIGURE 1 NUMBER OF NEW APPROVALS FOR DRUGS USED TO TREAT LIVER DISEASES, 2005- 2008
• FIGURE 2 HEPATITIS VACCINE: MARKET SHARE BY MANUFACTURER, 2008
• FIGURE 3 NUCLEOSIDE ANALOGS TO TREAT HEPATITIS: MARKET SHARE BY MANUFACTURER, 2008 (%)
• FIGURE 4 NUCLEOTIDE ANALOGS TO TREAT HEPATITS: MARKET SHARE BY MANUFACTURER, 2008 (%)
• FIGURE 5 INTERFERONS TO TREAT HEPATITIS: MARKET SHARE BY MANUFACTURER, 2008 (%)
• FIGURE 6 IMMUNE GLOBULINS TO TREAT HEPATITIS: MARKET SHARE BY MANUFACTURER, 2008 (%)
• FIGURE 7 CHEMOTHERAPY TO TREAT LIVER TUMORS: MARKET SHARE BY MANUFACTURER, 2008 (%)
• FIGURE 8 TARGETED THERAPY TO TREAT LIVER TUMORS: MARKET SHARE BY MANUFACTURER, 2008 (%)
• FIGURE 9 CHELATING AGENTS TO TREAT AUTOIMMUNE LIVER DISEASE: MARKET SHARE BY MANUFACTURER, 2008 (%)
• FIGURE 10 CORTICOSTEROIDS TO TREAT AUTOIMMUNE LIVER DISEASE: MARKET SHARE BY MANUFACTURER, 2008 (%)
• FIGURE 11 IMMUNOSUPPRESSIVE AGENTS TO TREAT AUTOIMMUNE LIVER DISEASE: MARKET SHARE BY MANUFACTURER, 2008 (%)
• FIGURE 12 ANTIMETABOLITES TO TREAT AUTOIMMUNE LIVER DISEASE: MARKET SHARE BY MANUFACTURER, 2008 (%)
• FIGURE 13 ANABOLIC STEROIDS TO TREAT ALCOHOL-INDUCED LIVER DISEASE: MARKET SHARE BY MANUFACTURER, 2008 (%)
• FIGURE 14 ALCOHOL ABUSE DRUGS: MARKET SHARE BY MANUFACTURER, 2008 (%)
• FIGURE 15 ANTI-REJECTION MEDICATION TO TREAT CHRONIC LIVER DISEASE: MARKET SHARE BY MANUFACTURER, 2008 (%)
• FIGURE 16 ANTI-INFECTIVES TO TREAT CHRONIC LIVER DISEASE: MARKET SHARE BY MANUFACTURER, 2008 (%)
• FIGURE 17 ANTIFUNGAL PROPHYLAXIS TO TREAT CHRONIC LIVER DISEASE: MARKET SHARE BY MANUFACTURER, 2008 (%)
• FIGURE 18 GALLSTONE STABILIZING AGENTS: MARKET SHARE BY MANUFACTURER, 2008 (%)
• FIGURE 19 OTHER DRUGS USED TO TREAT NON-ALCOHOLIC FATTY LIVER DISEASE: MARKET SHARE BY MANUFACTURER, 2008 (%)
• FIGURE 20 GLOBAL SALES OF DRUGS USED TO TREAT LIVER DISEASES, BY DISEASE TYPE, 2007-2014 ($ MILLIONS)
• FIGURE 21 GLOBAL SALES OF DRUGS TO TREAT HEPATITIS, 2007-2014 ($ MILLIONS)
• FIGURE 22 GLOBAL SALES OF DRUGS TO TREAT LIVER TUMORS, 2007-2014 ($ MILLIONS)
• FIGURE 23 GLOBAL SALES OF DRUGS TO TREAT AUTOIMMUNE DISEASES, THROUGH 2014 ($ MILLIONS)
• FIGURE 24 GLOBAL SALES OF DRUGS TO TREAT ALCOHOL-INDUCED LIVER DISEASES, 2007-2014 ($ MILLIONS)
• FIGURE 25 GLOBAL SALES OF DRUGS TO TREAT CHRONIC LIVER DISEASES, 2007-2014 ($ MILLIONS)
• FIGURE 26 GLOBAL SALES OF DRUGS TO TREAT NON-ALCOHOLIC FATTY LIVER DISEASES, 2007-2094 ($ MILLIONS)
• FIGURE 27 GLOBAL SALES OF DRUGS USED TO TREAT LIVER DISEASES, 2007-2014 ($ MILLIONS)
• FIGURE 28 SHARE OF DRUGS TO TREAT LIVER DISEASES, 2008 (%)
• FIGURE 29 GLOBAL SALES OF HEPATITIS VACCINE, 2007-2014 ($ MILLIONS)
• FIGURE 30 GLOBAL SALES OF NUCLEOSIDE ANALOGS TO TREAT LIVER DISEASES, BY REGION, 2007-2014 ($ MILLIONS)
• FIGURE 31 GLOBAL SALES OF NUCLEOTIDE ANALOGS TO TREAT LIVER DISEASES, BY REGION, 2007-2014 ($ MILLIONS)
• FIGURE 32 GLOBAL SALES OF INTERFERONS TO TREAT LIVER DISEASES, BY REGION, 2007-2014 ($ MILLIONS)
• FIGURE 33 GLOBAL SALES OF IMMUNE GLOBULINS TO TREAT LIVER DISEASES, BY REGION, 2007-2014 ($ MILLIONS)
• FIGURE 34 GLOBAL SALES OF CHEMOTHERAPY DRUGS TO TREAT LIVER DISEASES, BY REGION, 2007-2014 ($ MILLIONS)
• FIGURE 35 GLOBAL SALES OF TARGETED THERAPY TO TREAT LIVER CANCER, BY REGION, 2007-2014 ($ MILLIONS)
• FIGURE 36 GLOBAL SALES OF CHELATING AGENTS TO TREAT LIVER DISEASES, BY REGION, 2007-2014 ($ MILLIONS)
• FIGURE 37 GLOBAL SALES OF CORTICOSTEROIDS TO TREAT LIVER DISEASES, BY REGION, 2007-2014 ($ MILLIONS)
• FIGURE 38 GLOBAL SALES OF IMMUNOSUPPRESSIVE AGENTS TO TREAT LIVER DISEASES, BY REGION, 2007-2014 ($ MILLIONS)
• FIGURE 39 GLOBAL SALES OF ANTIMETABOLITES TO TREAT LIVER DISEASES, BY REGION, 2007-2014 ($ MILLIONS)
• FIGURE 40 GLOBAL SALES OF ANABOLIC STEROIDS TO TREAT LIVER DISEASES, BY REGION, 2007-2014 ($ MILLIONS)
• FIGURE 41 GLOBAL SALES OF ALCOHOL ABUSE DRUGS, BY REGION, 2007-2014 ($ MILLIONS)
• FIGURE 42 GLOBAL SALES OF ANTI-REJECTION MEDICATION TO TREAT LIVER DISEASES, BY REGION, 2007-2014 ($ MILLIONS)
• FIGURE 43 GLOBAL SALES OF INFECTION-FIGHTING DRUGS TO TREAT LIVER TRANSPLANT PATIENTS, BY REGION, 2007-2014 ($ MILLIONS)
• FIGURE 44 GLOBAL SALES OF ANTIFUNGAL PROPHYLAXIS IN LIVER TRANSPLANTS, BY REGION, 2007-2014 ($ MILLIONS)
• FIGURE 45 GLOBAL SALES OF GALLSTONE SOLUBILIZING AGENTS, BY REGION, 2007-2014 ($ MILLIONS)
• FIGURE 46 GLOBAL SALES OF OTHER DRUGS USED IN THE TREATMENT OF NON- ALCOHOLIC FATTY LIVER DISEASES, BY REGION, 2007-2014 ($ MILLIONS)
• FIGURE 47 TOTAL NUMBER OF PATENTS EACH YEAR, 2005- 2009
• FIGURE 48 NUMBER OF PATENTS BY TYPE, 2005- 2009
• FIGURE 49 PATENTS, SHARE BY TYPE, 2005- 2009 (%)
• FIGURE 50 TOTAL NUMBER OF PATENTS BY COUNTRY, 2005- 2009
• FIGURE 51 TOTAL NUMBER OF PATENTS BY COMPANY, 2005- 2009
• FIGURE 52 NUMBER OF PATENTS BY ASSIGNEE, 2005- 2009

関連商品